2 Information about pertuzumab
|
Marketing authorisation |
Pertuzumab (Perjeta, Roche) is indicated as 'adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer at high risk of recurrence'. |
|---|---|
|
Dosage in the marketing authorisation |
Intravenous 840 mg loading dose, then 420 mg every 3 weeks. Pertuzumab should be given with trastuzumab and chemotherapy for 1 year (maximum 18 cycles) for patients with high-risk disease, regardless of the timing of surgery. |
|
Price |
Pertuzumab costs £2,395 per 420‑mg vial; trastuzumab costs £407.40 per 150‑mg vial (excluding VAT; British national formulary online, accessed May 2018). The company has a commercial arrangement. This makes pertuzumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. |